Compare Stocks → Gold Mania (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:CRMDNASDAQ:INZYNASDAQ:VRCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.37+5.4%$1.57$0.78▼$2.48$286.84M0.943.16 million shs3.12 million shsCRMDCorMedix$5.84+8.8%$4.48$2.57▼$7.00$320.10M1.79945,462 shs1.03 million shsINZYInozyme Pharma$4.74+1.9%$5.73$2.69▼$7.80$293.20M1.54782,567 shs327,045 shsVRCAVerrica Pharmaceuticals$7.26+7.4%$6.02$2.86▼$7.76$307.97M1.82193,294 shs301,095 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%+2.24%-9.27%-16.97%+55.70%CRMDCorMedix0.00%+9.98%+30.94%+88.39%+15.87%INZYInozyme Pharma0.00%+6.76%-26.96%-10.73%-18.56%VRCAVerrica Pharmaceuticals0.00%+5.68%+13.08%+28.04%+11.18%Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.6662 of 5 stars3.52.00.04.01.90.80.6CRMDCorMedix1.7404 of 5 stars3.50.00.00.03.61.70.6INZYInozyme Pharma1.0408 of 5 stars3.51.00.00.00.03.30.0VRCAVerrica Pharmaceuticals3.8682 of 5 stars3.52.00.04.70.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00264.96% UpsideCRMDCorMedix3.00Buy$13.00122.60% UpsideINZYInozyme Pharma3.00Buy$17.00258.65% UpsideVRCAVerrica Pharmaceuticals3.00Buy$11.2554.96% UpsideCurrent Analyst RatingsLatest CRMD, VRCA, INZY, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/9/2024CRMDCorMedixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.004/9/2024CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.004/9/2024INZYInozyme PharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.004/9/2024INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.004/8/2024INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.003/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/13/2024CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.003/13/2024INZYInozyme PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/12/2024INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.00(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.47N/AN/A($0.16) per share-8.56CRMDCorMedix$60K5,334.84N/AN/A$1.28 per share4.56INZYInozyme PharmaN/AN/AN/AN/A$2.27 per shareN/AVRCAVerrica Pharmaceuticals$5.12M60.15N/AN/A$0.47 per share15.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/9/2024 (Confirmed)CRMDCorMedix-$46.34M-$0.92N/AN/AN/AN/A-72.31%-63.97%5/20/2024 (Estimated)INZYInozyme Pharma-$71.17M-$1.39N/AN/AN/AN/A-55.86%-40.71%5/14/2024 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)Latest CRMD, VRCA, INZY, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AAKBAAkebia Therapeutics-$0.09N/A+$0.09N/AN/AN/A 3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million3/12/2024Q4 2023CRMDCorMedix-$0.21-$0.26-$0.05-$0.26N/AN/A3/12/2024Q4 2023INZYInozyme Pharma-$0.31-$0.35-$0.04-$0.35N/AN/A2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03CRMDCorMedixN/A6.976.78INZYInozyme Pharma0.3213.3613.36VRCAVerrica Pharmaceuticals2.224.554.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CRMDCorMedix34.18%INZYInozyme Pharma88.30%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%CRMDCorMedix3.60%INZYInozyme Pharma11.88%VRCAVerrica Pharmaceuticals42.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.37 million201.33 millionOptionableCRMDCorMedix8254.81 million52.84 millionOptionableINZYInozyme Pharma5961.86 million54.51 millionOptionableVRCAVerrica Pharmaceuticals10042.42 million24.35 millionOptionableCRMD, VRCA, INZY, and AKBA HeadlinesSourceHeadlineVRCA Verrica Pharmaceuticals Inc.seekingalpha.com - May 3 at 11:22 PMVerrica Pharmaceuticals Inc (VRCA)investing.com - April 19 at 7:13 PMNeedham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)marketbeat.com - April 10 at 8:24 AMVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conferencemsn.com - April 4 at 11:15 AMStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossfinance.yahoo.com - April 3 at 8:23 AMVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:30 AMVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protectionmsn.com - March 31 at 11:37 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAfinanznachrichten.de - March 28 at 3:45 PMVerrica Pharma gains as FDA lists Ycanth in Orange Bookmsn.com - March 27 at 3:42 AMVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Factsmarkets.businessinsider.com - March 26 at 8:15 AMVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAglobenewswire.com - March 26 at 7:30 AMVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chatmsn.com - March 3 at 10:22 PMVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 2 at 10:39 AMWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?finance.yahoo.com - March 2 at 10:39 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 1 at 11:46 PMVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Ratingmarkets.businessinsider.com - March 1 at 6:46 PMBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansionmarkets.businessinsider.com - March 1 at 6:46 PMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:45 PMBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptancemarkets.businessinsider.com - February 29 at 10:09 PMVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 12:07 PMVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - February 29 at 7:30 AMEarnings Outlook For Verrica Pharmaceuticalsbenzinga.com - February 28 at 6:01 PMVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 27 at 7:30 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024finance.yahoo.com - February 22 at 10:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CorMedixNASDAQ:CRMDCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Inozyme PharmaNASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.